When is Cleerly the better choice?

Coronary plaque quantification from computed tomography is the product, aimed at a specific and contested clinical decision about who needs invasive testing. Depth in one disease with a real evidence base is a different proposition from opportunistic breadth across findings. For a cardiology service the analysis answers the question the service already asks every day.

When is Nanox.AI the better choice?

Its strategy is opportunistic population health, mining scans taken for another reason to find findings nobody was looking for, including vertebral fractures and coronary calcium. A deep clearance portfolio built over years across several anatomical findings, which is a harder path than a single authorisation. As a subsidiary of a listed parent, its business is described in filed disclosures that private competitors do not produce.

Cleerly vs Nanox.AI

Last VerifiedAugust 4, 2026

Verdict

Two ways to find coronary disease on a computed tomography scan. Cleerly analyses the coronary study a cardiologist ordered, quantifying plaque and stenosis to answer a contested question about who needs invasive testing. Nanox mines scans taken for entirely different reasons, surfacing coronary calcium and vertebral fractures nobody was looking for, with a clearance portfolio built over years and a listed parent whose filings describe the business. The difference is who asked the question. Cleerly answers one a clinician already posed; Nanox raises one nobody did, which is genuine population health and also generates follow up obligations the health system pays for. Price the incidental finding pathway alongside the licence, because the vendor does not carry it.

Select Cleerly if

Coronary plaque quantification from computed tomography is the product, aimed at a specific and contested clinical decision about who needs invasive testing.
Depth in one disease with a real evidence base is a different proposition from opportunistic breadth across findings.
For a cardiology service the analysis answers the question the service already asks every day.

Select Nanox.AI if

Its strategy is opportunistic population health, mining scans taken for another reason to find findings nobody was looking for, including vertebral fractures and coronary calcium.
A deep clearance portfolio built over years across several anatomical findings, which is a harder path than a single authorisation.
As a subsidiary of a listed parent, its business is described in filed disclosures that private competitors do not produce.

Attribute Matrix

Side by Side

Axis	C Cleerly	N Nanox.AI
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

Nanox.AI vs Riverain Technologies→Nanox.AI vs TeraRecon→Abstractive Health vs Regard→Abstractive Health vs xCures→AccurKardia vs Ceribell→AccurKardia vs Eko Health→

Disclosure

Opportunistic detection creates a duty to act whose cost falls on the health system rather than the vendor, since a surfaced finding generates follow up imaging, patient notification and an incidental finding pathway, and that should be priced alongside the licence. Nanox publishes no health privacy commitment, no data governance framework and no subgroup analysis, which is a notable gap for a product designed to run across whole populations. Neither vendor publishes performance stratified by sex, which matters because coronary disease presentation and calcium scoring both differ.